Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
about
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsHow could patient reported outcomes improve patient management in chronic myeloid leukemia?The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Severe agitation in depression precipitated by dasatinibGenomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid LeukemiaIncidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.Cancer-related fatigue--mechanisms, risk factors, and treatments.Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment.Expression of minichromosome maintenance 8 in chronic myelogenous leukemia.Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cellsPatient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Unmet Needs for Psychosocial Care in Hematologic Malignancies and Hematopoietic Cell Transplant.Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?Wage-subsidised employment as a result of permanently reduced work capacity in a nationwide cohort of patients diagnosed with haematological malignancies.Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients.Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor.Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.
P2860
Q27004032-95D453F0-54DC-4C85-B0BB-5793F10C6A35Q30241092-B131F10E-4F51-4668-B93C-18583AF0333AQ30964688-0336FA9C-8AF2-44A0-A8D3-6C9DD5EC6560Q34071562-7AB94CE0-0531-4541-B6CB-4744564C1BC2Q34781322-F27FDF7C-5AD2-4B1B-91A3-2E059F31F661Q35032345-F84AE9DE-6A5C-4C6F-8A86-0B6C902A90A0Q35252771-F03BEB0A-6A03-4B59-AE38-B2693B3294A3Q36332266-3DD91ECC-0C9D-45EB-A940-4AA93AF2EC37Q36368297-4D147C38-EB33-4A63-93AB-F62940D0A4E8Q36464373-2EF3EC4C-DFA2-487F-8561-23E48C613B24Q37409768-C324AA07-C5EC-47AB-9CC6-7269ADC7D1FFQ37676310-2B6CD303-7D18-4F02-BD27-BAC9852382BEQ37682689-F712BEA3-11D6-4222-92B0-84560C11B711Q38817270-210CDDEB-9CAD-4465-AC76-46514847560AQ38934423-C9C2B910-04DE-45FC-B3E5-A12905A1D388Q39569852-8DDE84A1-6FB6-4A8C-9B3E-24EB0CDA64E7Q39797514-F27FB5B8-F363-48C1-A4D0-576836322E62Q41264367-31142620-CC6B-405F-BE54-AEBD211EBFFCQ47551814-AA5B0E67-0573-426C-A700-26A2EC2FE056Q47747126-D651844A-C411-419C-AF77-43EDEBF47987Q47795207-AD3704EC-982F-41AB-9A6B-6106938D5D01Q48082559-29FA0E89-2366-4595-81A1-AD93C6536BDFQ48124245-AF298B87-C110-4A29-9287-A44070EE46D1Q48170931-FF8141D4-E3AA-4BA5-A739-030CBEF29F42Q50457803-6A98F41F-BEC4-459A-A10D-389D445DEA8CQ50586934-E8B4EB9E-22A9-4EEA-92D1-30BDEB151F31Q52612544-C6DBD5C2-7D93-447B-9D96-B421051739D8Q54222671-5DE93B56-F483-4376-887C-823FA2CF70A6
P2860
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Quality of life outcomes in pa ...... tors: a controlled comparison.
@en
Quality of life outcomes in pa ...... tors: a controlled comparison.
@nl
type
label
Quality of life outcomes in pa ...... tors: a controlled comparison.
@en
Quality of life outcomes in pa ...... tors: a controlled comparison.
@nl
prefLabel
Quality of life outcomes in pa ...... tors: a controlled comparison.
@en
Quality of life outcomes in pa ...... tors: a controlled comparison.
@nl
P2093
P2860
P50
P921
P1476
Quality of life outcomes in pa ...... itors: a controlled comparison
@en
P2093
Eduardo Sotomayor
Heather S L Jim
Javier Pinilla-Ibarz
Jeffrey Lancet
Kendra Sweet
Kristin M Phillips
Lubomir Sokol
Rami Komrokji
Sara Tinsley
P2860
P2888
P304
P356
10.1007/S00520-012-1630-5
P577
2012-11-20T00:00:00Z